RecruitingPhase 1NCT06938269

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWN109 Tablets in Healthy Adult Participants

Sponsor

Shanghai Minwei Biotechnology Co., Ltd

Enrollment

60 participants

Start Date

Jun 18, 2025

Study Type

INTERVENTIONAL

Conditions

Overweight or Obesity

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MWN109 tablet and a drug called Placebo for people with overweight or obesity. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.